NEW YORK (GenomeWeb) – Natera and Swiss biotech Amal Therapeutics plan to partner on a clinical trial to test Natera's bespoke circulating tumor DNA assay, Signatera, to assess treatment response in late-stage colorectal cancer patients.
The prospective clinical trial will assess Amal's cancer vaccine, ATP128, in combination with a PD-1 inhibitor in patients with stage IV colorectal cancer. Study investigators will use Signatera to measure patients' treatment response.